Business
Ascletis Announces Poster Presentations on the Study Results of ASC30 and ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA)
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S.
About this update from Ascletis Pharma, Inc.
[{"type":"text","content":"HONG KONG, June 8, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that poster presentations on preliminary studies of its oral small molecule GLP-1 Receptor (GLP-1R) agonist ASC30 and adipose-targeted, muscle-preserving weight loss drug candidate ASC47 will be presented at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago, U.S.","length":398,"tagName":"p"},{"type":"text","content":"Details of the Poster Presentations","length":35,"tagName":"p"},{"type":"text","content":"Poster Number: 750-P","length":20,"tagName":"p"},{"type":"text","content":"Abstract Title: ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study","length":141,"tagName":"p"},{"type":"text","content":"Session Type: General Poster Session","length":36,"tagName":"p"},{"type":"text","content":"Location: Poster Hall (Hall F1)","length":31,"tagName":"p"},{"type":"text","content":"Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time)","length":132,"tagName":"p"},{"type":"text","content":"Poster Number: 847-P","length":20,"tagName":"p"},{"type":"text","content":"Abstract Title: ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model","length":199,"tagName":"p"},{"type":"text","content":"Session Type: General Poster Session","length":36,"tagName":"p"},{"type":"text","content":"Location: Poster Hall (Hall F1)","length":31,"tagName":"p"},{"type":"text","content":"Presentation Time: Sunday Jun 22, 2025 12:30 PM - 1:30 PM (Chicago Time), i.e., Monday Jun 23, 2025 1:30 AM - 2:30 AM (Beijing Time)","length":132,"tagName":"p"},{"type":"text","content":"About ASC30 ","length":11,"tagName":"p"},{"type":"text","content":"ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044.","length":328,"tagName":"p"},{"type":"text","content":"About ASC47 ","length":11,"tagName":"p"},{"...